指南与共识炎症性肠病胃肠动力与功能性疾病

粪便微生物移植治疗复发性或难治性艰难梭菌感染及其他潜在适应症:英国胃肠病学会(BSG)与医疗感染学会(HIS)联合指南

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
指南 / 共识 · Gut · 2018-08-28

该联合指南由英国胃肠病学会与医疗感染学会联合工作组制定,聚焦粪便微生物移植治疗复发性或难治性艰难梭菌感染,并涉及非艰难梭菌感染领域的潜在应用;英国已有NICE 2014年指南,但缺乏明确的循证指南,本文件即为联合讨论的成果。

要点

  • 粪便微生物移植治疗复发性或难治性艰难梭菌感染的NICE 2014年指南已在英国获得认可。
  • 全球对粪便微生物移植治疗潜力的兴趣日增,尤其在复发性或难治性艰难梭菌感染领域。
  • 非艰难梭菌感染领域的应用证据正在涌现,英国粪便微生物移植服务主要涉及胃肠病学和微生物学/感染病学。

核心结论

  • 本指南由英国胃肠病学会与医疗感染学会联合工作组制定,旨在为粪便微生物移植的临床应用提供循证指导。

研究设计与样本

  • 英国胃肠病学会与医疗感染学会成立联合粪便微生物移植工作组,通过联合讨论制定本指南文件。

主要发现

  • 全球对粪便微生物移植治疗潜力的兴趣近年持续增加,尤其源于将其作为干预措施的随机研究。
  • 这些研究的主要焦点是治疗复发性或难治性艰难梭菌感染,非艰难梭菌感染领域的证据基础也在涌现。
  • 英国粪便微生物移植服务的主要临床相关方集中在胃肠病学和微生物学/感染病学两个专业领域。
  • NICE 2014年关于粪便微生物移植用于复发性或难治性艰难梭菌感染的指南已在英国获得认可,但英国缺乏明确的循证指南。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Mullish BH, Quraishi MN, Segal JP, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018. PMID: 30154172. doi:10.1136/gutjnl-2018-316818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。